Document is current
Any future updates will be listed below
-
Authors
van der Heijde, Désirée http://orcid.org/0000-0002-5781-158X
Landewé, Robert
- License Information
-
More Information
Article History
Received: 15 October 2019
Accepted: 30 October 2019
First Online: 6 November 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Désirée van der Heijde has received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma and is Director of Imaging Rheumatology BV. Robert Landewé has received Consulting fees and/or research grants from AbbVie, Ablynx, Amgen, AstraZeneca, Bristol-Myers Squibb, Centocor, Galapagos, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Roche, Schering, and UCB Pharma and is Director of Rheumatology Consultancy BV.
